Neuromyelitis optica (NMO) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Indication name: Neuromyelitis optica (NMO)

Neuromyelitis optica (NMO) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030; (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Neuromyelitis optica (NMO) is an autoimmune disease of the central nervous system (CNS) that predominantly affects the optic nerves and spinal cord. It is sometimes also referred to as NMO spectrum disorder. Neuromyelitis optica (NMO) is classified into relapsing form- which has periodic flare-ups, with some recovery in between. This is the more common kind, and women are far more likely to have this form than men. Monophasic form- which involves a single attack that lasts a month or two. Men and women get this type equally.

According to Thelansis there are an estimated 4,000 people with NMO in the United States and a quarter-million people worldwide. The prevalence of NMOSD is approximately 1.5 -11 per 100,000 individuals, although somewhat higher rates have been reported in countries with a higher proportion of individuals of African ancestry.

Competitive landscape of Neuromyelitis optica (NMO) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Neuromyelitis optica (NMO) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Biomarkers-AQP4-IgG, Th Lymphocytes, Genetic biomarkers- HLA-DPB1,e52 HLA-DRB1*03:01,e53,e54 PD-1.3A allele of PTPN22,e55 and CD226 Gly307Ser.e56 CYP7A1 gene G/G

Neuromyelitis optica (NMO) Market Forecasting: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing , Market Event and Product Event , Country specific Forecast Model, Market uptake and patient share uptake , Attribute Analysis , Analog Analysis , Disease burden and pricing scenario, Summary and Insights.

Read more: Neuromyelitis optica (NMO) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

S. No        Asset        Company                    Stage

1        Satralizumab        Hoffmann-La Roche        Phase 3

2        Ravulizumab        Alexion Pharmaceuticals Phase 3

3        Inebilizumab        MedImmune LLC Phase 2

4        BAT4406F        Bio-Thera Solutions Phase 1

5        NPB-01        Nihon Pharmaceutical Co., Ltd Phase 2

6        RC18 160 mg        RemeGen                Phase 3

7        HBM9161 Injection         Harbour BioMed (Guangzhou) Co. Ltd. Phase 1

8        SHR1459        Reistone Biopharma Company Limited Phase 2

9        Dalfampridine        Acorda Therapeutics Phase 2

10        ABX-1431 HCl        Abide Therapeutics Phase 1

11        BAF312        Novartis Pharmaceuticals        Phase 2